Bioprinting of miRNA-Induced Spheroids for Vascularized, Heterocellular Bone Regeneration.
Celik N., Yeware A., Pal V., Yeo M., Kim MH., Haugh L.
Animal Study, published in Chem Eng J (2026) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Chem Eng J (2026)
- Country
- Switzerland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 42559531
- DOI
- 10.1016/j.cej.2026.178521
Abstract (original English)
Successful bone regeneration requires coupled osteogenic and vascular development; however, achieving simultaneous multicellular differentiation within engineered tissues remains challenging. Here, we developed a microRNA (miR)-guided spheroid platform to induce dual osteogenic and endothelial differentiation of human adipose-derived stem cells (hASCs) for vascularized bone regeneration. hASCs were transfected with miR-148b or miR-210 to promote osteogenic and vascular-associated phenotypes, respectively, and assembled into spheroids that were bioprinted within an nHA-containing GelMA microgel environment using aspiration-assisted bioprinting (AAB). The integrated platform combined miR-guided osteogenic and endothelial differentiation, spatially organized AAB-based spheroid assembly, and an nHA-containing GelMA microgel environment to support vascularized bone tissue regeneration. The engineered constructs maintained high cell viability (> 90%) and supported active cell spreading and migration within the microgel matrix, together with increased osteogenic and endothelial gene expression. To further verify their in vivo regenerative potential, the constructs were implanted into mouse critical-size calvarial defects, where those containing miR-transfected hASCs improved bone regeneration, achieving ~91% of defect closure, and promoted the formation of vessel-like CD31-positive st
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.